We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
1. Current & emerging therapies for the management of patients with endometrial cancer
- Prof. Brian Slomovitz
-
2. Liquid biopsy
- Dr. Fabio Del Ben
-
3. Endometrial cancer: integrating molecular insights into personalized care
- Dr. Gemma Eminowicz
-
6. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
7. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
8. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
9. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
10. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
11. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
12. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
13. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
14. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
16. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
18. Comprehensive sickle cell care in the era of gene therapy
- Prof. Sophie Lanzkron
-
19. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
20. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
21. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
22. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
23. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
25. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
26. Hemophilia A
- Dr. Snejana Krassova
-
29. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
30. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
31. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
32. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
33. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
34. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
35. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
36. The impact of diet on natural killer cell metabolism and anti-tumor function
- Dr. Rebecca Delconte
-
37. Next-generation RNA vaccines
- Dr. Anna Blakney
-
38. Harnessing the immune system for cancer therapy
- Dr. Raghav Sundar
-
39. Rac-enhanced CAR immunotherapy: RaceCAR
- Prof. Denise Montell
-
40. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 1
- Prof. Kevin Harrington
-
41. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2
- Prof. Kevin Harrington
-
42. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
43. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
44. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
45. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
46. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
47. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
48. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
49. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
51. HCV resistance
- Prof. John Dillon
-
52. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
53. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
54. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
55. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
56. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
57. Cow’s milk allergy: the future
- Dr. Carina Venter
-
58. Cow's milk allergy: management
- Dr. Carina Venter
-
59. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
60. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
61. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
62. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
63. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
64. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
65. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
66. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
67. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
69. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
70. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
71. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
73. Huxley’s science fiction: ion channels in pain, pain resilience, and beyond
- Prof. Stephen Waxman
-
74. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
75. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
76. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
77. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
78. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
79. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
80. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
81. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
82. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
83. Gene manipulation applications in autoimmune diseases 1
- Dr. Leonardo M. R. Ferreira
-
84. Gene manipulation applications in autoimmune diseases 2
- Dr. Leonardo M. R. Ferreira
-
85. Gene manipulation applications in autoimmune diseases 3
- Dr. Leonardo M. R. Ferreira
-
86. Leveraging healthcare data through artificial intelligence
- Prof. Soma Sengupta
-
87. Integration of multi-omics data
- Prof. Ana Conesa
-
88. Bone marrow mesenchymal cells 1
- Prof. Arnold I. Caplan
-
89. Bone marrow mesenchymal cells 2
- Prof. Arnold I. Caplan
-
90. Peptide-drug conjugates as therapeutic modality in drug development 1
- Dr. Syed Faheem Askari Rizvi
-
91. Peptide-drug conjugates as therapeutic modality in drug development 2
- Dr. Syed Faheem Askari Rizvi
-
92. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
93. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
94. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
95. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
96. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
97. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
98. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
99. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
100. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
101. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
102. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
103. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
104. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
105. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
106. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
107. Diagnosis of tuberculosis and drug resistant tuberculosis 1
- Dr. Daniela Cirillo
-
108. Diagnosis of tuberculosis and drug resistant tuberculosis 2
- Dr. Daniela Cirillo
-
109. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
110. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
111. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
112. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
113. New drugs for asthma
- Prof. Peter Barnes
-
114. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
115. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
- Genetics & Genomics
-
116. An introduction to genetic association analysis
- Dr. Mark Iles
-
117. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
- Archived Lectures *These may not cover the latest advances in the field
-
119. AI and big data in drug discovery
- Mr. Ed Addison
-
120. Molecular brain imaging (PET) in diseases with dementia
- Prof. Emeritus Karl Herholz
Printable Handouts
Navigable Slide Index
- Introduction
- Genetic association
- Example of genetic association with disease risk
- Example of genetic association - continuous trait
- Basic test of genetic association
- Dominant model
- Recessive model
- Additive model
- Which genetic model?
- Logistic regression
- Logistic regression - dominant/recessive/additive
- Additive model - logistic regression
- Quantitative traits - linear regression
- Other regression models
- Genome-Wide Association Study (GWAS) - Manhattan plot
- Interpreting GWAS
- Causation
- GWAS of melanoma
- Covariates
- Type 2 diabetes example
- Confounding
- Population stratification
- Adjusting for population stratification
- Applying GWAS results - risk prediction
- Polygenic Risk Score (PRS)
- PRS in practice
- Other PRS applications
- Transcriptome-Wide Association Study (TWAS) & Mendelian Randomisation (MR)
- TWAS
- MR (1)
- MR (2)
- MR - example
- Summary
- Financial disclosures
Topics Covered
- Basic tests of genetic association
- Different genetic models
- Genome-Wide Association Study (GWAS)
- Polygenic risk score and its applications
- Transcriptome- Wide Association Study (TWAS)
- Mendelian Randomisation (MR)
Links
Series:
Categories:
External Links
Talk Citation
Iles, M. (2026, August 31). An introduction to genetic association analysis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved September 1, 2026, from https://doi.org/10.69645/EOIS4282.Export Citation (RIS)
Publication History
- Published on August 31, 2026
Financial Disclosures
- There are no commercial/financial matters to disclose.
A selection of talks on Genetics & Epigenetics
Transcript
Please wait while the transcript is being prepared...
0:00
Hi. I'm Mark Iles,
I'm an associate professor in
statistical genetics at
the University of Leeds.
I'm going to present you with
an introduction to genetic
association analysis.
0:12
First, what do we mean
by genetic association?
Genetic association is the
statistical association
between a genetic
variant and a trait.
A trait could be categorical,
for instance, whether or
not someone has a disease;
or it could be continuous,
such as height,
blood pressure, hormone levels.
For a disease trait,
if the frequency of
the disease varies by
genotype or equivalently,
genotype frequencies are
different in cases and controls,
then this is genetic
association.
0:40
Let's take an example
of genetic association
with disease risk.
Here we have a single
nucleotide polymorphism
or SNP, for short.
The alleles are A and G.
So three genotypes are
possible: AA, AG and GG.
The prevalence of asthma
varies according to genotype.
Amongst those with
the AA genotype,
325 out of every
100000 have asthma,
450 out of every 100000 for
those with the AG genotype
and 510 in every 100000
for the GG genotype.
Thus, the SNP is associated
with a risk of asthma.
1:16
Here we have a similar example
but for a continuous trait,
in this case, height.
We can see the distribution
of height varies by genotype.
The mean height is lowest in
those with an AA genotype
and highest in those
with a GG genotype.
1:30
Testing for association between
a trait and a genetic
variant is simple.
Again, we have genotypes AA,
AG and GG and a binary trait,
cases and controls
for disease here.
Tabulating the numbers of each
genotype for cases and controls,
we can see that the AA genotype
is less frequent in
cases than controls,
while the AG genotype
is slightly more frequent
in cases than controls,
and the GG genotype
is even more frequent
in cases than controls.
This suggests that
the G allele is
associated with increased
risk of disease.
We can test this formally
with a chi-squared test.
We can also estimate
the effect size by
calculating the odds ratio for
the AG genotype compared to
the AA genotype's baseline
and the GG genotype with again
the AA genotype's baseline.
Remember that if the
disease is rare,
the odds ratio approximates
to the relative risk.
This confirms that someone with
the AG genotype is at
increased risk of disease,
about 30% higher than someone
with the AA genotype,
while someone with
the GG genotype
is at about twice the risk.
This test makes no assumptions
about the underlying risk.
As is usual with
statistical tests,
making no assumptions is fine.
But if you can make
assumptions in your modelling
that are correct or
close to correct,
then you can
increase your power.
If we know or suspect that